Bafna Pharmaceuticals Ltd

AGM Details

• Date: 11 September 2026
• Time: 10:00 AM IST
• Mode: VC/OAVM
• Record date: 4 September 2026
• Book closure: 5–11 September 2026
• Remote e-voting: 8–10 September 2026

Resolutions Put to Vote

• Item 1: Adoption of Audited Financial Statements for FY 2025-26
• Item 2: Re-appointment of Upendar Mekala Reddy as Director
• Item 3: Ratification of Cost Auditor remuneration for FY 2026-27 (Ordinary Resolution)
• Cost Auditor remuneration: Rs 75,000 plus taxes

Dividend

• Dividend for FY 2025-26: not declared

Director Changes

• Navin Kumar retired as Independent Director on 22 June 2026
• Upendar Mekala Reddy proposed for re-appointment

Auditor Appointments

• Statutory Auditor: Brahmayya & Co., for five years through the 32nd AGM
• Internal Auditor: M/s K S Rao & Co. for 2026-27
• Cost Auditor: M/s N Sivashankaran & Co.; remuneration Rs 75,000; ratification requested

Material Related Party Transactions

• RPTs in FY26 were in ordinary course and arm's length; none requiring shareholder approval

Other Material Approvals

• Notice confirms VC/OAVM voting, e-voting via CDSL, and quorum mechanics

Financial performance

• Revenue from operations: 2,658.32; Total income: 2,849.42 for quarter ended 30 Jun 2026.
• YoY: revenue declined from 3,462.40 to 2,658.32; total income from 3,521.96 to 2,849.42.
• Profit before tax: 7.51; current quarter tax nil; basic EPS: 0.03.
• Total comprehensive income: 13.59; diluted EPS: 0.03.
• Total expenses: 2,841.91; major items: material consumed 1,431.50; depreciation 178.07.
• Auditors: Limited Review; results unaudited; GST matter emphasized.

AGM & corporate actions

• Board approved unaudited results for Q1 June 30, 2026; Limited Review Report.
• 31st AGM on Sep 11, 2026 at 10:00 AM IST via VC/OAVM.
• Register of Members and share transfer books closed Sep 5–11, 2026.
• Cut-off date for voting eligibility: Sep 4, 2026.

GST matter (emphasis of matter)

• GST demand of INR 235.47 Lakhs; refunds of INR 331.09 Lakhs under stay via Madras HC writ.
• Management confident of prevailing; no adverse financial outcome; no adjustments expected.

Meeting Details

• Board to meet on Tuesday, August 11, 2026; time and venue not disclosed.

Key Agenda Items

• Consider and approve Un-Audited financial results for quarter ended June 30, 2026.

Other Notes

• No other material governance or financial actions disclosed in this filing.

Dematerialisation processing status

• Dematerialisation requests for the quarter were processed and confirmed to depositories.
• Securities dematerialised have been listed on the stock exchanges where the earlier issued securities are listed.
• Physical certificates for dematerialisation were mutilated and cancelled after verification.
• Depository name updated as registered owner within the prescribed timeline.